Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Pulse Biosciences ( (PLSE) ) has issued an update.
Pulse Biosciences announced the appointment of Jon Skinner as Chief Financial Officer, effective February 3, 2025, to bolster its executive team as it scales the commercialization of its CellFX nanosecond PFA platform. Skinner, with extensive experience in financial leadership across healthcare and industrial sectors, brings strategic insights that are expected to aid in advancing Pulse Biosciences’ operational excellence and market positioning.
More about Pulse Biosciences
Pulse Biosciences, Inc. is a bioelectric medicine company focused on innovation in healthcare, leveraging its proprietary CellFX nsPFA technology for non-thermal cellular treatment, particularly targeting atrial fibrillation and other impactful healthcare markets. Headquartered in Miami, Florida, the company aims to improve patient quality of life through its novel technology.
YTD Price Performance: 17.65%
Average Trading Volume: 169,757
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $1.29B
For a thorough assessment of PLSE stock, go to TipRanks’ Stock Analysis page.
